Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved belantamab mafodotin-blmf, marketed as Blenrep, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior therapy lines.
The treatment targets BCMA, a major focus in myeloma therapy across antibody-drug conjugates, bispecifics and CAR-T approaches.
For clinicians, the approval adds another late-line combination option in a crowded but still high-need disease area.
Why It Matters
Myeloma care is being reshaped by BCMA-directed therapies and increasingly complex treatment sequencing.
What to Watch
Watch eye-toxicity monitoring, sequencing against bispecifics and CAR-T, and use outside academic centres.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAMultiple MyelomaAntibody-Drug ConjugateOncology